Zydus can continue commercial sales immediately, increasing near-term price competition against BMS’s Opdivo/Opdyta while the patent case proceeds. The order shifts the next procedural burden to BMS to produce a mapping-based infringement case in the High Court, tightening the window for any effective injunction with the patent set to expire on May 2. For oncology providers and payers, the ruling accelerates access to a lower-cost alternative (Zydus cites ~70% lower pricing) during the remaining patent term.